ArticleRadiation oncology journal2025
Promising application of nano-WO3/epoxy composite in intensity-modulated brachytherapy: a simulation study.
Article in Radiation oncology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Landscape and evolutionary trends of nanotechnology in cancer radiosensitization.Discover nano · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeImplementing intensity-modulated brachytherapy (IMBT) techniques with high-energy sources like 60Co has always been challenging due to the clinical limitations of the applicator dimensions. This study aims to investigate using tungsten trioxide nanoparticles/epoxy composite as a shielding material to enhance the protective properties of a redesigned applicator. MATERIALS AND
methodsThe Geant4 application to tomographic emission, the Geant4-based Monte Carlo dose calculation engine (version 9.0), was used to simulate the shielding composite and the IMBT technique with a voxelated patient-based phantom. To evaluate the effectiveness of the new shielding material, IMBT plans created with the redesigned applicator were compared with those with a conventional applicator. 60Co and 192Ir were utilized, and in the same high-risk clinical target volumes D90, the D2cc for the bladder and rectum were evaluated in 18 patients with vaginal cancer.
resultsFor the IMBT plans with the 60Co source, the use of the redesigned applicator decreased the D2cc of the bladder and rectum by 11.1% and 12.8%, respectively, while for those with the 192Ir source, the reduction was 16.6% and 18.7%, respectively. Nevertheless, there was an insignificant alteration in the absorbed dose parameter (D90) for the target using both sources.
conclusionThis study demonstrates that tungsten trioxide nanoparticle/epoxy composite can be advantageous in tackling radiation shielding concerns. Enhancing the shielding properties of this composite, considering the size limitations of applicators, leads to improved protection of organs at risk, such as the bladder and rectum. This substance can be considered a promising shielding material in the construction of applicators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.